Drug Type Small molecule drug |
Synonyms- |
Target- |
Action- |
Mechanism- |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Multiple Sclerosis | Phase 2 | United States | 07 Jun 2022 | |
Post Acute COVID 19 Syndrome | Phase 1 | United States | 30 Apr 2025 | |
Alzheimer Disease | Phase 1 | United States | 17 Aug 2021 | |
Amyotrophic Lateral Sclerosis | Phase 1 | United States | 17 Aug 2021 | |
Parkinson Disease | Phase 1 | United States | 17 Aug 2021 | |
Depressive Disorder, Major | Phase 1 | United States | 20 Jul 2021 |
Phase 2 | 7 | hwdjzjyqcr(sebduaqiii) = ycjagfdaje hmtwrdowqc (dzwdmjhfjt, 0.112) View more | - | 27 Jun 2024 | |||
Not Applicable | - | - | [11C]PS13 PET scans with ketoprofen | cjfveuvgvr(yndntsuokv) = The average binding potential (BP_ND) across the brain regions was 1.1 lcmsbkzglb (rkqodjdonq ) View more | - | 09 Jun 2024 | |
Not Applicable | - | - | 11 C-PS13 (11C-PS13) | pircocicbw(ennbxanrwv) = emqcxvhpzd qpatorotyj (vwthqapnvb, 0.6) View more | - | 21 May 2019 |